Project Grant R01EY037126
Award Date
2/1/25
Completion Date
1/31/29
Dollars Obligated
$618K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Eye Institute (NEI) awarded a $191,095 Project Grant (CFDA 93.867 - Vision Research) to the University of North Texas Health Science Center at Fort Worth. This two-year grant, effective September 1, 2024, supports research to investigate how changes in cellular metabolism and extracellular matrix signaling in the optic nerve head contribute to the development of pathological fibrosis in glaucoma. The project aims to establish the role of the YAP/TAZ transcriptional pathway in...
This federal Project Grant award of $2,260,440 from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) will support research to investigate the molecular, cellular, and transcriptional mechanisms regulating astrocyte reactivity in glaucoma and other optic neuropathies. The research aims to establish how compartmentalized cAMP signaling and the cell cycle inhibitor p21CIP control astrocyte proliferation, microglial/macrophage activation, and retinal ganglion cell...
This $246,000 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) will support research by the University of Texas Southwestern Medical Center to identify and characterize gene/protein defects and molecular pathways that lead to early-onset glaucoma. The researchers will employ a high-throughput, unbiased forward genetics pipeline to screen for genes associated with inner retinal thinning, a hallmark of early-onset glaucoma. The project...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), will fund research to investigate the combined effects of aging and elevated intraocular pressure (IOP) on the development of glaucoma and the retinal ganglion cell (RGC) transcriptome. The $679,159 award, with a project period from May 1, 2025 to April 30, 2029, will be used to (1) demonstrate how AAV2-mediated epigenetic reprogramming with the OSK (OCT4, SOX2, KLF4)...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), provides $387,428 to The Research Foundation For The State University Of New York to investigate mechanisms underlying optic nerve sensitivity to elevated intraocular pressure, a major risk factor for glaucoma. The key objectives are to: 1) Determine how optic nerve head astrocytes integrate transient biomechanical strains to predispose to future glaucomatous...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $526,841 to Vanderbilt University Medical Center (VUMC) to investigate the role of cGMP signaling in the development of glaucoma. The research aims to determine how disruptions in cGMP signaling lead to retinal ganglion cell degeneration and vision loss in glaucoma. The 5-year project, which began on February 1, 2025, will use cell-specific transgenics, viral-targeted...
The National Eye Institute (NEI) awarded a $147,486 Project Grant under the Vision Research program (CFDA 93.867) to The Johns Hopkins University. The grant supports research to evaluate the regenerative potential of human retinal ganglion cells (RGCs) and optic nerve (ON) formation, with the goal of developing regenerative therapies to restore vision in patients with diseases like glaucoma that cause irreversible RGC and ON degeneration. The project will leverage the naturally regenerative...
The National Eye Institute (NEI) awarded a $132,597 Project Grant under the NEI Vision Research program (CFDA 93.867) to The Schepens Eye Research Institute, Inc. The grant supports research aimed at improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The project will investigate the role of neural activity in regulating host RGC integration and remodeling of host-donor visual neural circuits. The research involves developing models to selectively inhibit host RGC...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), will support research to investigate the underlying cellular and synaptic mechanisms that drive changes in retinal ganglion cell (RGC) activity following two mouse models of optic nerve injury. The $460,625 award, with a project period from September 30, 2024 to September 29, 2026, will be used to (1) determine the specific cellular and synaptic mechanisms responsible for...
The National Eye Institute (NEI) awarded a $360,897 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotechnology research company, with a period of performance from September 30, 2024 to August 31, 2025. The grant supports the development of a novel combination therapy approach for glaucoma, which involves topical application of an optimized nerve growth factor (NGF) mutein (HC201) and oral supplementation with nicotinamide (NAM). The goal of the Phase 1 study is to...